The Probability of Being in Response (PBR): A Novel Efficacy Endpoint for Chronic Graft Versus Host Disease (GvHD) Applied to the Reach-3 Study of Ruxolitinib Versus BAT

被引：0
|
作者：
Hollaender, Norbert [1 ]
Glimm, Ekkehard [1 ]
Gauvin, Jennifer [2 ]
Stefanelli, Tommaso [1 ]
Zeiser, Robert [3 ]
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Univ Freiburg, Fac Med, Med Ctr, Dept Med 1, Freiburg, Germany
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159432
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10521 / 10522
页数：2
相关论文
共 50 条
  • [1] THE PROBABILITY OF BEING IN RESPONSE: A NOVEL EFFICACY ENDPOINT FOR CHRONIC GRAFT VERSUS HOST DISEASE APPLIED TO THE REACH-3 STUDY OF RUXOLITINIB VERSUS BAT
    Hollaender, Norbert
    Glimm, Ekkehard
    Gauvin, Jennifer
    Stefanelli, Tommaso
    Zeiser, Robert
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 313 - 313
  • [2] A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study
    Norbert Hollaender
    Ekkehard Glimm
    Jennifer Gauvin
    Tommaso Stefanelli
    Robert Zeiser
    Bone Marrow Transplantation, 2024, 59 : 12 - 16
  • [3] A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study
    Hollaender, Norbert
    Glimm, Ekkehard
    Gauvin, Jennifer
    Stefanelli, Tommaso
    Zeiser, Robert
    BONE MARROW TRANSPLANTATION, 2024, 59 (01) : 12 - 16
  • [4] EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE AFTER CROSSOVER IN THE PHASE 3 REACH-3 STUDY
    Russo, Domenico
    Locatelli, Franco
    Teshima, Takanori
    Lee, Stephanie J.
    Li, Xuechan
    Stefanelli, Tommaso
    Gowda, Maanasa
    Zeiser, Robert
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 63 - 64
  • [5] REACH-3 trial design: A Phase 3, Randomized Study to Assess Ruxolitinib over BAT in Patients with Corticosteroid-Refractory Chronic Graft-versus-Host Disease Post Allo-HSCT
    Zeiser, Robert
    Ram, Ron
    Foley, Stephen Ronan
    Yeshurun, Moshe
    Locatelli, Franco
    Gadbaw, Brian
    Atienza, Edric
    Hollaender, Norbert
    Teshima, Takanori
    BONE MARROW TRANSPLANTATION, 2018, 53 : 444 - 446
  • [6] Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease
    Hurabielle, C.
    de Fontbrune, F. Sicre
    Moins-Teisserenc, H.
    Robin, M.
    Jachiet, M.
    Coman, T.
    Dhedin, N.
    Cassius, C.
    Chasset, F.
    de Masson, A.
    Michonneau, D.
    Bagot, M.
    Bergeron, A.
    Socie, G.
    de Latour, R. Peffault
    Bouaziz, J-D
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E206 - E208
  • [7] Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
    Shiratori, Souichi
    Fukushima, Kentaro
    Onishi, Yasushi
    Doki, Noriko
    Goto, Tatsunori
    Okada, Masaya
    Nakamae, Hirohisa
    Maeda, Yoshinobu
    Kato, Koji
    Ishikawa, Takayuki
    Kondo, Tadakazu
    Toyosaki, Masako
    Ikeda, Takashi
    Uchida, Naoyuki
    Maki, Akio
    Shimada, Fumika
    Tajima, Takeshi
    Stefanelli, Tommaso
    Teshima, Takanori
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (06) : 705 - 716
  • [8] Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis
    Denk, Alexander
    Mittermaier, Cornelia
    Weber, Daniela
    Fante, Matthias
    Gunes, Sibel
    Edinger, Matthias
    Herr, Wolfgang
    Wolff, Daniel
    ANNALS OF HEMATOLOGY, 2024, 103 (09) : 3755 - 3764
  • [9] Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study
    Zeiser, Robert
    Russo, Domenico
    Ram, Ron
    Hashmi, Shahrukh K.
    Chakraverty, Ronjon
    Middeke, Jan Moritz
    Musso, Maurizio
    Giebel, Sebastian
    Uzay, Ant
    Langmuir, Peter
    Hamad, Nada
    Li, Xuechan
    Gowda, Maanasa
    Stefanelli, Tommaso
    Lee, Stephanie J.
    Teshima, Takanori
    Locatelli, Franco
    BLOOD, 2023, 142
  • [10] Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study
    M Arora
    J Pidala
    C S Cutler
    X Chai
    B Kurland
    D A Jacobsohn
    S Z Pavletic
    J Palmer
    G Vogelsang
    M Jagasia
    K Schultz
    S J Lee
    Leukemia, 2013, 27 : 1196 - 1201
12345